Inhibrx (INBX)
(Real Time Quote from BATS)
$34.59 USD
+0.10 (0.29%)
Updated May 17, 2024 02:08 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
INBX 34.59 +0.10(0.29%)
Will INBX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INBX
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
INBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Other News for INBX
JMP Securities Remains a Hold on Inhibrx (INBX)
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Inhibrx (INBX)
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
As more rare disease therapies launch, their prices are rising